Samsung Biologics Expands its Collaboration with Pfizer for the Long-Term Manufacturing of Biosimilars Portfolio
Shots:
- The companies expand their collaboration for the long-term commercial manufacturing of Pfizer’s multi-product portfolio, based on an initial manufacturing agreement signed in Mar 2023 for a specific Pfizer product
- Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio covering oncology, inflammation, and immunology & uses its newest facility, Plant 4, for the manufacturing
- Additionally, Pfizer continues to partner with Samsung Biologics to provide better treatment options for patients globally
Ref: Samsung Bioepis | Image: Samsung Bioepis
Related News:- Samsung Bioepis Presented Results of SB12 (biosimilar, eculizumab) for the treatment of Paroxysmal Nocturnal Hemoglobinuria at EHA 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
